1.The antisaccade in children with autistic spectrum disorders
International Journal of Pediatrics 2010;37(5):521-523
Recent studies demonstrate that autistic spectrum disprders children have deficits in executive functiony, particularly the function referred response inhibition. The antisaccade task provides a new tool for direct evaluation of inhibitory function and a new way to explore the character of response inhibition in children with cognitive impairment. Researchers have used the technologies of eye movement to reveal the ability of oculomotor inhibition in children with autistic spectrum disprders, which is poorer than that of normal children.
2.Review of Foreign Medical Education Management
Chinese Journal of Medical Education Research 2006;0(10):-
The state of scale management,structure of hierarchy,professional institutions,educational system and degree,situation of academy and cost of medical education in developed countries was summarized in this article respectively to provide reference for our medical education reform.
3.Soft regulation of inflammatory immune responses
Chinese Pharmacological Bulletin 2016;32(3):297-303
Inflammation reaction and immune response are in-separable in the levels of system, tissue, cell and molecule. In-flammatory immune responses ( IIR) is proposed in this paper, which is defined a moderate or abnormal system responses of in-flammatory immune related cells in responding to the internal and external environment changes of body. It is described briefly that the research progresses of inflammatory immune cells ( e. g. , macrophages, dendritic cells, T cells and B cells, etc. ) and non-inflammatory immune cells ( e. g. , glial cells, endothe-lial cells, epithelial cells, fibroblasts, synovial cells and liver cells, etc. ) , and cytokines/receptor signal transduction in-volved in IIR. Moreover, the existing problems about regulating IIR drugs clinically are summarized. It is firstly put forward that soft regulation of inflammatory immune responses ( SRIIR) is a new direction of discovery and development of new drugs for the treatment of IIR related diseases.
4.Comparative study of spray characteristics of domestic and foreign nasal spray delivery devices for live attenuated nasal influenza vaccine
Chinese Journal of Biologicals 2023;36(11):1291-1296
Objective To compare the spray characteristics of domestic and foreign nasal spray delivery devices for live attenuated influenza vaccine(LAIV). Methods The particle size distribution(DV10,DV50 and DV90),the proportion of droplets smaller than 10 μm and Span of atomized particles of two brands of nasal spray delivery devices at home and abroad were measured by laser diffraction method,the spray pattern[maximum diameter(D_(max)),shortest diameter(D_(min))and ovality(D_(max)/D_(min))]and spray geometry(spray angle and width)were detected by Spray view,and the comparative analysis was performed. Results There was no significant difference in DV10,DV50,DV90 particle size distribution,proportion of droplets smaller than 10 μm and Span of atomized particles between the two kinds of domestic and foreign nasal spray delivery devices[F-values of Levene's test for equality of variances were 0. 622,0. 135,3. 067,0. 212 and 0. 058,P-values were0. 434,0. 714,0. 085,0. 647 and 0. 810,and significance(two-tailed)values of equal variances assumed were 0. 439,0. 228,0. 281,0. 539 and 0. 910,respectively];D_(max),D_(min)and ovality of the spray patterns showed no significant difference[F-values of Levene's test for equality of variances were 2. 102,2. 666 and 0. 514,P-values were 0. 158,0. 114 and0. 479,and significance(two-tailed)values of equal variances assumed were 0. 651,0. 407,and 0. 160,respectively];The geometric mean ratios of spray angle and width were 0. 92 and 0. 91,respectively,which ranged from 0. 90 to 1. 11.Conclusion Both the domestic and foreign nasal spray delivery devices meet the delivery requirement of the nasal spray LAIV,which can be used for the delivery of nasal spray vaccines and drugs.
5.The clinical analysis of recombinant human endostatin hormone combined with transcatheter arterial chemoembolization of primary hepatocellular carcinoma for 52 patients
Chinese Journal of Postgraduates of Medicine 2014;37(17):26-29
Objective To study the effect of recombinant human endostatin hormone combined with transcatheter arterial chemoembolization (TACE) for the treatment of primary hepatocellular carcinoma (HCC).Methods Fifty-two primary HCC patients were divided into combined group (26 patients) and control group (26 patients) by random digits table method.The patients in combined group received TACE and recombinant human endostatin hormone added in embolism emulsion.The recent curative effect,level of serum vascular endothelial growth factor (VEGF),adverse reactions,recurrence rate and survival rate were compared between two groups.Results The response rate(RR) and clinical benefit rate(DCR) in combined group were 57.69%(15/26),84.62%(22/26),in control group were 34.62%(9/26),73.08%(19/26),there were significant differences (x2 =5.237,P < 0.05 ; x2 =4.284,P < 0.05).The 7th,14th,28th day after TACE,the level of VEGF in two groups was first increased and then a downward trend,the difference were statistically significant (P < 0.05).The level of VEGF in combined group was significantly lower than that in control group (P< 0.05).The follow up rate was 94.23%(49/52),the 1-year and 2-year recurrence rate in combined group was significantly lower than that in control group (P< 0.05).The 2-year and 3-year survival rate in combined group was significantly higher than that in control group (P < 0.05).Conclusion With TACE plus recombinant human endostatin hormone can effectively inhibit the increase of serum VEGF level,improve curative effect and disease control rate,reduce tumor recurrence and improve survival rate.
6.The analysis of relevant factors influencing the prognosis of progressive cerebral infarction
Chinese Journal of Primary Medicine and Pharmacy 2013;20(12):1783-1785
Objective To explore the relevant factors influencing the prognosis of progressive cerebral infarction,in order to provide basis for clinical trentment and improve the prognosis of patients.Methods Clinical data of 163 patients admitted as progressive cerebral infarction and 355 patients admitted as non-progressive cerebral infarction were retrospectively analyzed.All patients were followed up by interview or telephone at the time of 30 and 90days,the clinical data were recorded.The relevant factors influencing the prognosis of progressive cerebral infarction were analyzed.Results Multiple linear regression analysis of patients with progressive cerebral infarction showed that total anterior circulation infarcts,respiratory infection,coronary heart disease history,imbalance of water and electrolyte,white blood cell increasing were leading influence risk factors for the higher National Institutes of Health Stroke Scale(NIHSS) in hospitalized patients.Analysis of patients with progressive cerebral infarction showed that total anterior circulation infarcts,lack of physical activity,NIHSS at admitting,the elderly and respiratory infection were leading influence risk factors of the higher Activities of Daily Living(ADL) and modify Rankin Scale(mRS) scores at 30d and 90d of following up.The scores of ADL and mRS at 30d and 90d were significantly higher in progressive cerebral infarction than those of non-progressive cerebral infarction patients (t =6.6179,P =0.000,t =5.2788,P =0.000,t =5.0608,P =0.000,t =4.0725,P =0.000,respectively).The recurrence of cerebral infarction in progressive cerebral infarction group and death events at 30d were also significantly higher than that of non-progressive cerebral infarction(x2 =8.423,P =0.004 and x2 =5.135,P =0.023,respectively).But the recurrence of progressive cerebral infarction and death events at 90d,there were no significant differences between progressive cerebral infarction and non-progressive cerebral infarction (x2 =1.938,P =0.159 and x2 =3.518,P =0.061,respectively).Conclusion The relevant factors influencing the prognosis of progressive cerebral infarction are common effect of various factors.In the treatment of progressive cerebral infarction should be actively considered as much as possible to improve the prognosis of patients.
7.Clinical observation of leflunomide in the treatment of diabetic nephropathy-Ⅳ
Clinical Medicine of China 2013;29(11):1199-1202
Objective To investigate the curative effect of leflunomide in the treatment of diabetic nephropathy-Ⅳ (DN-Ⅳ).Methods Sixty cases with DN-Ⅳ were assigned to the leflunomide treatment group and the control group.Both groups were given hypoglycemic,antihypertensive,regulate lipid and angiotensin converting enzyme inhibitors or angiotensin Ⅱ inhibitor class of drugs.Meanwhile patients in the treatment group were orally administered leflunomide once daily for two month with a dose of 50 mg/d in the first three days and 20 mg/d afterwards.24 hour pre-and post-treatment values of urinary protein,C-reactive protein (CRP),endogenous creatinine clearance rate (Ccr),triglyceride (TG),total cholesterol (TC),albumin (ALB),glycosylated hemoglobin (HbA1c) and blood pressure were measured.Analyzed the correlation of Ccr with other laboratory indicators after treatment for one year.Results At 24 hour before treatment,after treatment for two months and one year,the level of 24 h urinary protein of the treatment group (n =26) were (3.75 ± 0.94)g/24 h,(2.02 ± 0.45) g/24 h,and (2.46 ± 0.55) g/24 h respectively,and the level of Ccr were (69.04 ± 13.35) ml/min,(71.35 ± 11.25) ml/min,and (67.48 ± 10.58) ml/min respectively.While in the control group(n =28),the 24 h urinary protein level of were (3.68 ± 1.03) g/24 h,(3.43 ± 0.65) g/24 h,and (5.46 ±0.47) g/24 h respectively at the three time points,and the Ccr level were (68.55 ± 10.09) ml/min,(66.76 ± 9.45) ml/min,(57.50 ± 15.75) ml/min respectively.The levels of 24 h urinary protein in the treatment group after treatment for two months and one year were significantly lower than before treatment in the treatment group as well as at the corresponding period of the control group (P < 0.05),while the level of Ccr in the treatment group was higher than that of the control group at the same period,and the difference was statistically significant(P < 0.05).The levels of CRP,TG,TC,HbAlc and systolic pressure in the treatment group after treatment for two months and one year were significantly lower than that of control group at the same period,while ALB was significantly higher than before treatment in the treatment group as well as at the corresponding period of the control group (P < 0.05).The 24 h urine protein,TC,systolic blood pressure were significantly correlated with Ccr after treatment for one year (β =-0.771,-0.682,0.656,-0.530respectively;P <0.01).Conclusion Leflunomide treatment of diabetic nephropathy was safe and effective,but the duration of leflunomide treatment and second selection time of leflunomide therapy needed to further study.
8.The roles of amyloid βprotein in neurovascular unit injiny
International Journal of Cerebrovascular Diseases 2009;17(12):926-930
The deposition of amyloid β-protein (Aβ is the key pathological basis of cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). The current studies emphasis that the stability of internal environment between cells of the neurovascular unit is the key to maintain normal brain function. This article reviews the relationship between the Aβand the neurovascular unit injury, and we expect to provide some new ideas for the clinical prevention and treatment of CAA and AD.
10.Angiogenesis in rheumatoid arthritis
Chinese Pharmacological Bulletin 2003;0(10):-
Indices of angiogenesis are increased in synovia from patients with rheumatoid arthritis, and vascu-lar proliferation may contribute to the pathogenesis of synovitis, pan nus growth, bone and cartilage destruction, and osteophyte formation. Many proan giogenic factors are expressed in the synovium in RA. They have been shown to ha ve important effects in the angiogenic process in RA. So the blockade of angioge nesis appears to be a promising avenue for the future treatment of RA.